Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.